Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence (2nd stage)
Pendent de resolució
Oficina de Projectes Internacionals
IMI2 - Innovative Medicines Initiative 2016
Tipo de ayuda
- Grups de Recerca (GRU)
- Investigadors/es (INV)
Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.
This trend for new, effective therapies creates more treatment options for patients. However, it confronts physicians with an increasingly expanding number of potential therapeutic options, which each need to be understood and adopted effectively. To become familiar with the huge volume of available information, physicians need to learn continuously about medical guideline changes and marketed treatments. In conclusion, future decision-making processes will become ever-more complex, with the potential outcome of sub-optimal or even incorrect treatment choices being made. Furthermore, some patients have disease characteristics for which evidence of guideline recommendations is scarce and physicians lack information about real-world treatment outcomes. Hence, the challenges to be addressed are assisted guideline-based decision-making and the discovery of knowledge about treatment outcomes in real-world settings. As the latter challenge requires analysis of large data sets, the application of Artificial Intelligence (AI) will be a key technology.
Bases de la convocatoria
Web con más información
Fecha de publicación
Fecha de inicio de solicitudes
Fecha de presentación en la UAB
Fecha de fin de solicitudes en el Organismo convocante
Fecha de resolución prevista